TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study

Inclusion Criteria

• •To be eligible for the study, subjects are required to enter the LTS Study within 14 days of exiting the Maintenance Study of Protocol 0157 and must meet all the following criteria:
• •Capable of providing informed consent, which must be obtained prior to any study related procedures.
• •One of the following:
• •* Those who demonstrated persistent loss of response (no improvement 8 weeks after meeting loss of response criteria) OR
• •* Two Clinical Flares after an episode of loss of response during the Maintenance Study OR
• •* Those who have completed the Maintenance Study and confirmation of clinical remission status results are available
• •During the study and for 7 days after receiving the last dose of the study drug, females of childbearing potential or men capable of fathering children must agree to use highly effective birth control measures (failure rate \<1% when used consistently and correctly)) or agree to abstain from sexual intercourse. Females of childbearing potential must test negative for pregnancy at Day 1
• •All male subjects must agree to refrain from semen donation during the study and for 7 days after the last dose of study drug.
• •Must be able and willing to adhere to the study visit schedule and comply with other study requirements.